Press Releases Castle Biosciences, Inc.

Equities

CSTL

US14843C1053

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
21.53 ^USD	+5.85%		+9.79%	-0.23%

Apr. 08	Castle Biosciences Insider Sold Shares Worth $441,853, According to a Recent SEC Filing	MT
Apr. 04	Castle Biosciences, Inc. Announces Share New Data At the 20Th European Association of Dermato-Oncology Congress	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024	Apr. 11	BU
Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations	Apr. 10	BU
Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year	Apr. 10	BU
Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer	Apr. 04	BU
Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference	Apr. 02	BU
Castle Biosciences Announces Updates to its Board of Directors	Mar. 27	BU
Castle Biosciences, Inc. - Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx-Melanoma Test Result Were Recurrence Free at Three Years	Mar. 25	AQ
Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year	Mar. 25	BU
Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB	Mar. 22	BU
Castle Biosciences - Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy	Mar. 20	AQ
Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy	Mar. 19	BU
New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences’ IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older	Mar. 15	BU
Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences and MedTech Investor Forum	Mar. 13	AQ
Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum	Mar. 12	BU
Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting	Mar. 08	BU
Castle Biosciences - In Novel Cohort, New Data Confirms DecisionDx-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk Subgroups	Mar. 08	AQ
In Novel Cohort, New Data Confirms DecisionDx®-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk Subgroups	Mar. 07	BU
Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results	Feb. 28	BU
Castle Biosciences - Study Finds DecisionDx-Melanoma Significantly Improves the Risk Stratification of Patients with Stage I Melanoma Compared to American Joint Committee on Cancer 8th Edition Staging	Feb. 27	AQ
Study Finds DecisionDx®-Melanoma Significantly Improves the Risk Stratification of Patients with Stage I Melanoma Compared to American Joint Committee on Cancer 8th Edition Staging	Feb. 26	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Castle Biosciences, Inc.

Equities

CSTL

US14843C1053

Press Releases

Filters